Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees

Journal of Neuroscience

Volumn 27, Issue 23, 2007, Pages 6174-6184

  Klunk, William E ^a,e   Price, Julie C ^a   Mathis, Chester A ^a   Tsopelas, Nicholas D ^a   Lopresti, Brian J ^a   Ziolko, Scott K ^a   Bi, Wenzhu ^a   Hoge, Jessica A ^a   Cohen, Ann D ^a   Ikonomovic, Milos D ^a   Saxton, Judith A ^a   Snitz, Beth E ^a   Pollen, Daniel A ^b   Moonis, Majaz ^b   Lippa, Carol F ^c   Swearer, Joan M ^b   Johnson, Keith A ^d   Rentz, Dorene M ^d   Fischman, Alan J ^d   Aizenstein, Howard J ^a   DeKosky, Steven T ^a   more..

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Diagnosis; Pittsburgh compound B; Positron emission tomography; Striatum

Indexed keywords

AMYLOID; PRESENILIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; PEDIGREE; POPULATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; CORPUS STRIATUM; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PEDIGREE; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1;

EID: 34249984684     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0730-07.2007     Document Type: Article

References (87)

1. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T, Fox NC, Rossor MN (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145-147.
2. Becker JT, Boller F, Saxton J, McGonigle-Gibson KL (1987) Normal rates of forgetting of verbal and non-verbal material in Alzheimer's disease. Cortex 23:59-72.
3. Benton AL (1968) Differential behavioral effects in frontal lobe disease. Neuropsychologia 6:53-60.
4. Benton AL, Sivan AB, Hamsher KD, Varney NR, Spreen O (1994) Contributions to neuropsychological assessment. A clinical manual, Ed 2. New York: Oxford UP.
5. Beyreuther K, Dyrks T, Hilbich C, Monning U, Konig G, Multhaup G, Pollwein P, Masters CL (1992) Amyloid precursor protein (APP) and beta A4 amyloid in Alzheimer's disease and Down syndrome. Prog Clin Biol Res 379:159-182.
6. Bland JM, Altman DG (1995) Multiple significance tests: the Bonferroni method. BMJ 310:170.
7. Borkowski JG, Benton AL, Spreen O (1967) Word fluency and brain damage. Neuropsychologia 5:135-140.
8. Braak H, Braak E (1990) Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 49:215-224.
9. Brilliant MJ, Elble RJ, Ghobrial M, Struble RG (1997) The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol Appl Neurobiol 23:322-325.
10. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25:7709-7717.
11. Buschke H (1984) Cued recall in amnesia. J Clin Neuropsychol 6:433-440.
12. Campion D, Flaman JM, Brice A, Hannequin D, Dubois B, Martin C, Moreau V, Charbonnier F, Didierjean O, Tardieu S, Penet C, Puel M, Pasquier F, Ledoze F, Bellis G, Calenda A, Heilig R, Martinez M, Mallet J, Bellis M, et al. (1995) Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet 4:2373-2377.
13. Cruts M, Van Broeckhoven C (1998) Presenilin mutations in Alzheimer's disease. Hum Mutat 11:183-190.
14. Cutler NR, Haxby JV, Duara R, Grady CL, Moore AM, Parisi JE, White J, Heston L, Margolin RM, Rapoport SI (1985) Brain metabolism as measured with positron emission tomography: serial assessment in a patient with familial Alzheimer's disease. Neurology 35:1556-1561.
15. Drzezga A, Grimmer T, Henriksen G, Wester HJ, Kurz A, Schwaiger M (2006) Imaging of cerebral amyloid plaque load and glucose metabolism in semantic dementia and Alzheimer's disease. J Nucl Med 47 [Suppl 1]:73P.
16. 18F]FDG PET study. Neurology 68:501-508.
17. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129:2805-2807.
18. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, Larossa GN, Spinner ML, Klunk WE, Mathis CA, Dekosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Ann Neurol 59:512-519.
19. Fahn S, Elton RL (1987) Unified Parkinson's disease rating scale. In: Recent developments in Parkinson's disease (Fahn S, Marsden CD, Calne D, Goldstein M, eds), pp 153-164. Florham Park, NJ: Macmillan Health Care Information.
20. Ferrer I, Boada R, Sanchez G, Rey MJ, Costa-Jussa F (2004) Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 14:11-20.
21. Folstein M, Folstein S, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198.
22. Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B (2006) Mild cognitive impairment. Lancet 367:1262-1270.
23. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-1562.
24. Guze BH, Hoffman JM, Mazziotta JC, Baxter LR, Jr., Phelps ME (1992) Positron emission tomography and familial Alzheimer's disease: a pilot study. J Am Geriatr Soc 40:120-123.
25. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. Nat Neurosci 1:355-358.
26. Hardy JA, Higgins GA (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science 256:184-185.
27. Haroutunian V, Perl D, Purohit D, Marin D, Khan K, Lantz M, Davis K (1998) Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer's disease. Arch Neurol 55:1185-1191.
28. Hollander M, Wolfe DA (1973) Nonparametric statistical methods. New York: Wiley.
29. Ikonomovic MD, Uryu K, Abrahamson EE, Ciallella JR, Trojanowski JQ, Lee VM, Clark RS, Marion DW, Wisniewski SR, DeKosky ST (2004) Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 190:192-203.
30. Ikonomovic MD, Abrahamson EE, Isanski BA, Mathis CA, DeKosky ST, Klunk WE (2006) X34, a histofluorescent marker of abnormal protein aggregates with amyloid structure, in neuropathological studies of preclinical and clinical Alzheimer's disease. Methods Enzymol 412:123-144.
31. Joachim CL, Selkoe DJ (1992) The seminal role of beta-amyloid in the pathogenesis of Alzheimer disease. Alzheimer Dis Assoc Disord 6:7-34.
32. Joachim CL, Morris JH, Selkoe DJ (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135:309-319.
33. 11C]PIB uptake in Alzheimer disease. Neurology 67:1575-1580.
34. Kennedy AM, Rossor MN, Frackowiak RS (1995) Positron emission tomography in familial Alzheimer disease. Alzheimer Dis Assoc Disord 9:17-20.
35. Klein WL (2006) Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease. Alzheimers Dement 2:43-55.
36. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319.
37. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA (2005) Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25:10598-10606.
38. Kyriakides T, Silbert PL, Kakulas BA (1994) Cerebral amyloid angiopathy and intracerebral hemorrhage with special reference to the pons. Clin Neuropathol 13:71-76.
39. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, George-Hyslop SP, Roses AD, Pollen DA (1996) Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology 96:406-412.
40. Logan J, Fowler AH, Volkow ND, Wang G-J, Ding Y-S, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16:834-840.
41. Lopez OL, Becker JT, Klunk W, Saxton J, Hamilton RL, Kaufer DI, Sweet RA, Cidis Meltzer C, Wisniewski S, Kamboh MI, DeKosky ST (2000) Res evaluation and diagnosis of probable Alzheimer's disease over the last two decades. I. Neurology 55:1854-1862.
42. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, Dekosky ST, Price JC (2005) Simplified Quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 46:1959-1972.
43. Mann DM, Pickering-Brown SM, Takeuchi A, Iwatsubo T (2001) Amyloid angiopathy and variability in amyloid beta deposition is determined by mutation position in presenilin-1linked Alzheimer's disease. Am J Pathol 158:2165-2175.
44. Masliah E, Hansen L, Adame A, Crews L, Bard F, Lee C, Seubert P, Games D, Kirby L, Schenk D (2005) Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64:129-131.
45. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE (2003) Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46:2740-2754.
46. Matsushita S, Arai H, Okamura N, Ohmori T, Takasugi K, Matsui T, Maruyama M, Iwatsubo T, Higuchi S (2002) Clinical and biomarker investigation of a patient with a novel presenilin-1 mutation (A431V) in the mild cognitive impairment stage of Alzheimer's disease. Biol Psychiatry 52:907-910.
47. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34:939-944.
48. Minoshima S, Frey KA, Foster NL, Kuhl DE (1995) Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr 19:541-547.
49. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446-452.
50. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA (2005) Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 65:323-325.
51. Morris JC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43:2412-2414.
52. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C (1989) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:1159-1165.
53. Morris JC, Storandt M, McKeel Jr DW, Rubin EH, Price JL, Grant EA, Berg L (1996) Cerebral amyloid deposition and diffuse plaques in "normal" aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-719.
54. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 9:448-452.
55. Pastor P, Goate AM (2004) Molecular genetics of Alzheimer's disease. Curr Psychiatry Rep 6:125-133.
56. Perez SE, Lazarov O, Koprich JB, Chen EY, Rodriguez-Menendez V, Lipton JW, Sisodia SS, Mufson EJ (2005) Nigrostriatal dysfunction in familial Alzheimer's disease-linked APPswe/PSΔE9 transgenic mice. J Neurosci 25:10220-10229.
57. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183-194.
58. Poorkaj P, Sharma V, Anderson L, Nemens E, Alonso ME, Orr H, White J, Heston L, Bird TD, Schellenberg GD (1998) Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene. Hum Mutat 11:216-221.
59. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, Dekosky ST, Mathis CA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25:1528-1547.
60. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 45:358-368.
61. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 68:1205-1212.
62. Reitan RM (1958) Validity of the trail-making tests as an indication of organic brain damage. Percept Motor Skills 8:271-276.
63. Ridha BH, Barnes J, Bartlett JW, Godbolt A, Pepple T, Rossor MN, Fox NC (2006) Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 5:828-834.
64. Rossor MN, Kennedy AM, Frackowiak RS (1996) Clinical and neuroimaging features of familial Alzheimer's disease. Ann NY Acad Sci 777:49-56.
65. Saxton J, Ratcliff G, Newman A, Belle S, Fried L, Yee J, Kuller L (2000) Cognitive test performance and presence of subclinical cardiovascular disease in the cardiovascular health study. Neuroepidemiology 19:312-319.
66. Schott JM, Fox NC, Frost C, Scahill RI, Janssen JC, Chan D, Jenkins R, Rossor MN (2003) Assessing the onset of structural change in familial Alzheimer's disease. Ann Neurol 53:181-188.
67. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760.
68. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P, Read S, Satyamurthy N, Petric A, Huang SC, Barrio JR (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24-35.
69. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652-2663.
70. St George-Hyslop PH (1999) Molecular genetics of Alzheimer disease. Semin Neurol 19:371-383.
71. Styren SD, Kamboh MI, DeKosky ST (1998) Expression of differential immune factors in temporal cortex and cerebellum: the role of alpha-1- antichymotrypsin, apolipoprotein E, and reactive glia in the progression of Alzheimer's disease. J Comp Neurol 396:511-520.
72. Styren SD, Hamilton RL, Styren GC, Klunk WE (2000) X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48:1223-1232.
73. Suenaga T, Hirano A, Llena JF, Yen SH, Dickson DW (1990) Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol (Berl) 80:280-286.
74. Tanzi RE, Kovacs DM, Kim TW, Moir RD, Guenette SY, Wasco W (1996) The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 3:159-168.
75. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791-1800.
76. Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G, Brouwers N, Van den Broeck M, Vennekens K, Corsmit E, Cruts M, De Strooper B, Van Broeckhoven C, Vandenberghe R (2006) Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum Mutat 27:888-896.
77. 11C]SB-13 PET. Am J Geriatr Psychiatry 12:584-595.
78. 11C-PIB PET imaging in the differential diagnosis of dementia. J Nucl Med 47 [Suppl 1]:74P.
79. Wahlund LO, Basun H, Almkvist O, Julin P, Axelman K, Shigeta M, Jelic V, Nordberg A, Lannfelt L (1999) A follow-up study of the family with the Swedish APP 670/671 Alzheimer's disease mutation. Dement Geriatr Cogn Disord 10:526-533.
80. Wechsler D (1997) Wechsler Adult Intelligence Scale, Ed 3. New York: The Psychological Corporation.
81. Welsh-Bohmer KA, Butters N, Mohs RC (1994) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). V. A normative study of the neuropsychological battery. Neurology 44:609-614.
82. Whitaker C, Eckman C, Almeida C, Feinstein D, Atwood C, Eckman E, Crutcher K, Hersh L, Leissring M, LaVoie M, Ertekin-Taner N, Shapiro P, Takahashi R, Yamin R, Mansourian S, Estus S, Lesne S, Turner T, Farris W, Stroebel G (2003) Live discussion: amyloid-beta degradation: the forgotten half of Alzheimer's disease. J Alzheimers Dis 5:491-497.
83. Wilson AA, Garcia A, Chestakova A, Kung HF, Houle S (2004) A rapid one-step radiosynthesis of the beta-amyloid imaging radiotracer N-methyl-[C-11]2-(4′-methylaminophenyl)-6hydroxybenzothiazole ([C-11]-6-OH-BTA-1). J Label Compd Radiopharm 47:679-682.
84. Xia W, Ostaszewski BL, Kimberly WT, Rahmati T, Moore CL, Wolfe MS, Selkoe DJ (2000) FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gammasecretase cleavage complex. Neurobiol Dis 7:673-681.
85. Younkin SG (1997) The APP and PS1/2 mutations linked to early onset familial Alzheimer's disease increase the extracellular concentration and A beta 1-42 (43). Rinsho Shinkeigaku 37:1099.
86. 11C] Pittsburgh compound B dynamic PET studies. J Nucl Med 47 [Suppl 1]:117P.
87. Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ, Dekosky ST, Price JC (2006) Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. NeuroImage 33:94-102.